RUSH-funded research by Harvard University’s Till Barnighausen was presented at the Conference On Retroviruses And Opportunistic Infections, showing male life expectancy in rural South Africa improving far less dramatically than female life expectancy since the introduction of antiretroviral therapy. Women have suffered the disproportionate burden of HIV infection. However, with the scale-up of antiretroviral therapy (ART), women have been found to have higher rates of HIV testing, start on antiretroviral treatment earlier, have better adherence and retention to treatment, and...read full post
RethinkHIV is a consortium of senior researchers from London School of Hygiene & Tropical Medicine, Imperial College London, Harvard School of Public Health, Centre for the Study of African Economies and Blavatnik School of Government at Oxford University.
The consortium will evaluate new evidence related to the costs, benefits, effects, fiscal implications, and developmental impacts of HIV interventions in sub-Saharan Africa, in order to maximise contributions to the fight against HIV there.
The aim of RethinkHIV is to find ways of creating, optimising, and sustaining fiscal space for domestic HIV investment, as well as exploring long-term, sustainable national and international financing mechanisms. RethinkHIV is funded by RUSH Foundation.